Can we avoid the toxicity of chemotherapy in elderly cancer patients?
Por:
Feliu J, Heredia-Soto V, Gironés R, Jiménez-Munarriz B, Saldaña J, Guillén-Ponce C and Molina-Garrido MJ
Publicada:
1 nov 2018
Resumen:
Although approximately 50% of cancer patients are 70 years of age or older, cancer treatment in the elderly remains a therapeutic challenge. The elderly form a very heterogeneous group in relation to their general health state, degree of dependence, comorbidities, performance status, physical reserve and geriatric situation, for which therapeutic decisions must be made in an individualized manner. In addition, changes in pharmacokinetics and pharmacodynamics of the drugs occur with age, as well as the tolerance of the tissues, leading to a narrowing of the therapeutic margin and an increase in toxicity.
In the general population, Performace Status (PS) has traditionally been used to estimate tolerance to chemotherapy, but in the elderly population it is not useful. In this review we summarize the current knowledge about the pharmacology of antineoplastic drugs in the elderly and the tools available to help us identify risk of chemotherapy toxicity in these patients.
Filiaciones:
Feliu J:
Medical Oncology Dpt. H. Universitario La Paz, Madrid, CIBERONC, Spain
Heredia-Soto V:
Medical Oncology Dpt. H. Universitario La Paz, Madrid, CIBERONC, Spain
:
Medical Oncology Dpt. H. Lluís Alcanyís, Xàtiva, Valencia, Spain
Jiménez-Munarriz B:
Medical Oncology Dpt. H. Universitario Clara Campal, Madrid, Spain
Saldaña J:
Medical Oncology Dpt. Instituto Catalán de Oncología, Hospitalet, Barcelona, Spain
Guillén-Ponce C:
Medical Oncology Dpt. H. Universitario Ramón y Cajal, Madrid, Spain
Molina-Garrido MJ:
Medical Oncology Dpt. H. Virgen de la Luz, Cuenca, Spain
|